- Global Pharma News & Resources

Suono Bio, Inc. Announces Formulation-Agnostic Platform for the Delivery of RNA Therapeutics

FOXBOROUGH, Mass.--(BUSINESS WIRE)--Suono Bio, Inc., the company revolutionizing the treatment of gastrointestinal diseases, today announced its latest publication in the Journal of Pharmaceutical Sciences demonstrating the capability to deliver unformulated RNA therapeutics against relevant disease targets in the gastrointestinal tract.

This latest publication adds to the validation of Suono Bio’s therapeutic delivery platform leveraging low-frequency ultrasound for formulation-agnostic delivery. This technology was originally developed in the laboratory of Institute Professor Robert Langer at MIT to facilitate rapid, local administration of therapeutics to treat serious diseases.

“Therapeutic translation of oligos has been hampered by delivery and bioavailability issues with a complicated landscape for chemical-based formulations. This further demonstrates our capability to deliver RNAs and siRNAs to knockdown relevant gene targets without the need for any formulation.” said Dr. Carl Schoellhammer, corresponding author, and Suono Bio co-founder.

In addition to previously demonstrating the preclinical use of siRNAs for treating inflammatory conditions, this latest publication demonstrates the ability to knockdown endogenous genes, including Ctnnb1, the gene encoding for beta-catenin, which plays a role in tumorigenesis in colorectal cancers, for example. The publication may be read for free here:


Suono Bio was founded by Robert Langer and Giovanni Traverso, a gastroenterologist and biomedical engineer from the Department of Mechanical Engineering, MIT and Brigham and Women’s Hospital, Harvard Medical School, and Dr. Carl Schoellhammer. The company is developing therapeutic products for inflammatory-mediated diseases leveraging their ultra-rapid and formulation independent delivery technology. Suono Bio’s platform enables rapid, localized delivery of small molecules, biologics, and nucleic acids and gene therapies without the need for encapsulation of the therapeutic. For more information, please visit


Carl Schoellhammer

Editor Details

  • Company:
    • Businesswire
Last Updated: 05-Jan-2022